Recent Data Validate Shorter Radiation Duration in Prostate Cancer

Video

Trial results presented at a recent medical conference demonstrated that the use of shorter duration radiation is safe and effective in prostate cancer, as well as a type of rare cancer, according to an expert.

Findings from a trial with 7 years of follow-up have confirmed that treatment with hypofractionated radiation—fewer radiation treatments at larger doses—is both safe and effective in patients with prostate cancer, according to an expert.

Louis Potters, MD, FACR, FABS, FASTRO, spoke with CancerNetwork® about some of the standout developments in the radiation oncology space presented in the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Potters, who is the chair of the Department of Radiation Medicine and deputy physician-in-chief of Northwell Health Cancer Institute In New Hyde Park, New York, highlighted findings from the PCS5 trial (NCT01444820), which indicated the non-inferiority of using hypofractionated radiotherapy to treat patients with prostate cancer compared with conventional fractionation.1

Additionally, he spoke about results from another trial (NCT02494700) showing that low-dose radiation for patients with orbital indolent B-cell lymphoma successfully demonstrated disease control and reduced toxicity.2

Transcript:

In the prostate area, there was further affirmation of the PCS5 trial with 7-year data now affirming the utilization of hypofractionation as a non-inferior study without an increase in toxicity or [adverse] effects. That just further validates the utilization of a shorter treatment course as definitive care for prostate cancer. There was a great study that was presented from the MSK group on the use of low-dose radiation for ocular lymphomas and utilizing very low doses to avoid the complications associated with treating an orbit or an eye with radiation therapy. They've been able to demonstrate successful disease control as well as less toxicity and/or complications.

References

  1. Niazi TM, Nabid A, Malagon T, et al. Conventional vs. hypofractionated, radiotherapy for high-risk prostate cancer: 7-year outcomes of the randomized, non-inferiority, phase 3 PCS5 trial. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 4. Accessed November 7, 2022.
  2. Pinnix CC, Dabaja B, Gunther JR, et al. Response adapted ultra low dose radiation therapy for the definitive management of orbital indolent B-cell lymphoma. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 3. Accessed November 7, 2022.
Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
Related Content
Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

American Society for Radiation Oncology Names Vivek S. Kavadi as CEO

Roman Fabbricatore
June 25th 2024
Article

Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

Russ Conroy
April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer

Russ Conroy
March 20th 2024
Article

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Evidence Shows Racial Disparities in Radiation Oncology for Breast Cancer

Russ Conroy
March 8th 2024
Article

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.